NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
This article was originally published in The Tan Sheet
Executive Summary
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration